Guided Therapeutics, Inc.
GTHP
$0.25
$0.0525.00%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 883.33% | -48.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 883.33% | -48.72% | |||
| Cost of Revenue | 428.00% | -34.21% | |||
| Gross Profit | 1,208.57% | -55.70% | |||
| SG&A Expenses | 241.51% | -45.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 188.15% | -38.07% | |||
| Operating Income | -102.14% | 36.44% | |||
| Income Before Tax | -64.15% | 8.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -64.15% | 8.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -64.15% | 8.51% | |||
| EBIT | -102.14% | 36.44% | |||
| EBITDA | -102.36% | 36.45% | |||
| EPS Basic | -53.13% | 11.93% | |||
| Normalized Basic EPS | -82.00% | 23.08% | |||
| EPS Diluted | -47.00% | 8.26% | |||
| Normalized Diluted EPS | -82.00% | 23.08% | |||
| Average Basic Shares Outstanding | 3.56% | 3.62% | |||
| Average Diluted Shares Outstanding | 3.56% | 3.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||